BNTX - BioNTech SE

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in EUR. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
17,310,600
17,310,600
18,976,700
482,325
108,589
Cost of revenue
4,532,000
4,532,000
3,860,700
704,362
243,827
Gross profit
12,778,600
12,778,600
15,116,000
-222,037
-135,238
Operating expenses
Research development
-
-
-
645,029
226,466
Selling general and administrative
544,200
544,200
328,900
108,561
43,410
Total operating expenses
477,800
135,900
200,100
-139,620
46,280
Operating income or loss
12,300,800
12,642,700
14,915,900
-82,417
-181,518
Interest expense
16,200
18,900
5,400
64,949
1,718
Total other income/expenses net
623,700
623,700
156,300
-52,896
2,341
Income before tax
12,954,100
12,954,100
15,046,400
-145,802
-179,440
Income tax expense
3,519,700
3,519,700
4,753,900
-161,000
-268
Income from continuing operations
9,434,400
9,434,400
10,292,500
15,198
-179,172
Net income
9,434,400
9,434,400
10,292,500
15,198
-179,056
Net income available to common shareholders
9,434,400
9,434,400
10,292,500
15,198
-179,056
Basic EPS
-
38.78
42.18
0.06
-0.85
Diluted EPS
-
37.77
39.63
0.06
-0.85
Basic average shares
-
243,280
244,000
253,300
211,500
Diluted average shares
-
249,786
259,700
253,300
211,500
EBITDA
-
13,096,300
15,127,000
-42,109
-143,826